Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 9Not yet recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 390Neoplasms 382Lung Neoplasms 266Multiple Myeloma 246Colorectal Neoplasms 235Neoplasm Metastasis 217Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 166Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 141Carcinoma, Renal Cell 141Lymphoma 137Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 124Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 119Head and Neck Neoplasms 115Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 100Lymphoma, Follicular 96Sarcoma 95

Interventions

Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic cancer, adult × 1 year × Clear all
NCT03854110 2025-09-11

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Geistlich Pharma AG

Phase 1 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic cancer, adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡